Milrinone for persistent pulmonary hypertension of the newborn
- 10 November 2010
- journal article
- review article
- Published by Wiley in Emergencias
- Vol. 2010 (11), CD007802
- https://doi.org/10.1002/14651858.cd007802.pub2
Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation with inhaled nitric oxide (iNO). However, iNO is not available in all countries and not all infants will respond to iNO. Milrinone is a phosphodiesterase III inhibitor which induces pulmonary vasodilatation by its actions through a cyclic adenylate monophosphate mediated signaling pathway. To assess efficacy and safety in infants with PPHN either treated with: milrinone compared with placebo or no treatment; milrinone compared with iNO; milrinone as an adjunct to iNO compared with iNO alone; milrinone compared with potential treatments for PPHN other than iNO. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2010), MEDLINE and EMBASE databases from their inception until January 2010. We searched the reference lists of potentially relevant studies without any language restriction. Fully published randomized controlled trials (RCTs) and quasi‐RCTs comparing milrinone with placebo, iNO or potential treatments other than iNO in neonates with PPHN were included if trials reported any clinical outcome. We found no studies meeting the criteria for inclusion in this review. We found no studies meeting the criteria for inclusion in this review. The efficacy and safety of milrinone in the treatment of PPHN are not known and its use should be restricted within the context of RCTs. Such studies should address a comparison of milrinone with placebo (in clinical situations where iNO is not available) or, in well resourced countries, should compare milrinone with iNO or as an adjunct to iNO compared with iNO alone.Keywords
This publication has 19 references indexed in Scilit:
- Randomized Trial of Milrinone Versus Placebo for Prevention of Low Systemic Blood Flow in Very Preterm InfantsThe Journal of Pediatrics, 2009
- Extracorporeal membrane oxygenation for severe respiratory failure in newborn infantsEmergencias, 2008
- Inhaled nitric oxide for respiratory failure in preterm infantsPublished by Wiley ,2007
- Sildenafil for pulmonary hypertension in neonatesPublished by Wiley ,2007
- Population pharmacokinetics and dosing regimen design of milrinone in preterm infantsArchives of Disease in Childhood: Fetal & Neonatal, 2007
- Nitric oxide for respiratory failure in infants born at or near termPublished by Wiley ,2006
- Population Pharmacokinetics of Milrinone in Neonates with Hypoplastic Left Heart Syndrome Undergoing Stage I ReconstructionAnesthesia & Analgesia, 2006
- Neonatal Persistent Pulmonary Hypertension Treated with Milrinone: Four Case ReportsNeonatology, 2006
- Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart DiseaseCirculation, 2003
- Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory FailureThe New England Journal of Medicine, 1997